LCC uses cookies for security and to improve your experience on our site. You can view our cookie policy here

About Liverpool ChiroChem

An established, chemical technology innovator, on a mission to accelerate the discovery and development of high-quality drugs


Imagine a future in which the drug discovery community has access to the novel
and rationally-designed compounds it needs to make life-changing discoveries



A Brief History of LCC

The company started in 2014, based on the discoveries made in the Xiao group at the University of Liverpool, about the enantioselective reduction of pyridines to the corresponding chiral piperdines.

The Xiao group rapidly realised the potential of these researches, as many marketed drugs contain substituted piperidine rings. These initial discoveries led to the formation of LCC.

Since then, we’ve enhanced the scope of our expertise to provide leading scientific organisations around the world with access to chirally-pure compounds that play their part in small molecule drug discovery.


The Future is Now

Our chemical technologies enable access to unique, 3D-rich, chiral building blocks, that were previously scarce.

LCC provides:

  • Access to 3D-rich, novel, enantiopure chemical space for use in orthogonal hit-ID approaches (FBLD, DEL, VLS etc)
  • Efficient follow-on chemistry support via in-house Parallel Synthesis Lab with liquid handling and custom plating options
  • Personalised, collaborative support using our design and computational team to expedite specific chemical space exploration




Headquarters - Runcorn, United Kingdom

We have moved to new labs in Runcorn to facilitate the combination of our production facilities with our R&D and PSL teams.

The move also allows LCC to keep expanding our team and capabilities as we continue to accelerate your discovery.

Contact us

Core Technologies & Strengths

Our initial success was based on the catalytic enantioselective reduction of pyridines, however we have continued to enhance the scope of our expertise, to provide a broad range of chiral (N-)heterocycles.

Our experience allows us to utilise various approaches including asymmetric hydrogenation reactions, catalytic cross-couplings, and cyclisation chemistries. Our highly skilled R&D team can support your projects to give access to innovative new therapies.

  • Design and synthesis of novel chiral variants of privileged scaffolds using specialist synthetic technologies
  • Synthons with high purity (≥95%, ≥95% e.e.) and confirmed stereochemistry
  • Parallel synthesis laboratory to synthesise up to 1,000 compounds per month (per client)
  • Design team with computational chemist to explore chemical space of your choice (including focused libraries, near neighbour analogues etc.)

DEL Synthons Fragment Libraries Linkers Virtual Libraries

Our expert team

Every member of LCC (past and present), have contributed in shaping LCC into who we are today. The combination of skillsets, along with excellent team-spirit, focus, and forward-thinking have allowed LCC to innovate within our field. The LCC Team continue to achieve our goal in supporting our customers to expedite drug discovery.


Senior Leadership Team

Paul Colbon, PhD

CEO & Founder

Caroline Couturier

Head of Finance & Company Secretary

Malcolm Stewart


Chris Swain, PhD


Scientific Advisory Board

Prof. Jianliang Xiao, PhD


Steve Djuric, PhD


Prof. Brian Cox, PhD


Department Heads

Ilaria Proietti Silvestri, PhD

Head of Product Design

Mark Barnes

Operations Manager


Tony Huxley

Head of Chemistry